Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa’ italiana di Ginecologia E Ostetricia)

Ferrandina, Gabriella; Aristei, Cynthia; Biondetti, Pietro; Cananzi, Ferdinando Carlo Maria; Casali, Paolo; Ciccarone, Francesca; Colombo, Nicoletta; Comandone, Alessandro; Corvò, Renzo; Iaco, Pierandrea De; Tos, Angelo Paolo Dei; Donato, Vittorio; Fiore, Marco; Franchi, Massimo Piergiuseppe; Gadducci, Angiolo; Gronchi, Alessandro; Guerriero, S.; Infante, Amato; Odicino, Franco; Pirronti, Tommaso; Quagliuolo, Vittorio; Sanfilippo, Roberta; Testa, Antonia Carla; Zannoni, Gian Franco; Scambia, Giovanni; Lorusso, Domenica

doi:10.1016/j.ejca.2020.08.016

Cited by 29 publications

(37 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a lack of consensus on risk factors and optimal treatment due to their rarity and diversity in their histopathology, thus generally leading to poor outcomes. Leiomyosarcoma (LMS), undifferentiated sarcoma and endometrial stromal sarcoma (ESS) are the predominant uterine sarcomas, with even rarer types such as rhabdomyosarcoma (including embryonal type in the cervix), and adenosarcomas [4,77].…”

Section: Mirnas In Uterine Sarcomasmentioning

confidence: 99%

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Fiore

Suleiman

Pentimalli

et al. 2021

IJMS

View full text Add to dashboard Cite

Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of ∼22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.

show abstract

Section: Mirnas In Uterine Sarcomasmentioning

confidence: 99%

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Fiore

Suleiman

Pentimalli

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Natural course and optimal treatments are currently unclear 5 . Surgery is the cornerstone of its treatment, and despite a lack of strong evidence for effective adjuvant therapy, chemotherapy and radiotherapy should be offered 5 . Angioinvasion begins with the infiltration of myometrial veins with further extension through ovarian veins into the IVC.…”

Section: First Author Age Presentation Misdiagnosis Diagnosis Symptoms Surgery Primary Tumor Time Of Recurrence (M) Site Of Recurrence Mementioning

confidence: 99%

“…A new chemotherapy was then administered and the patient is free of the disease 12 months after treatment. HG‐ESS is rarer than LG‐ESS; it recurs more frequently and earlier, and is usually diagnosed at advanced stage with a 5‐year survival rate of 35% 5 . HG‐ESS is often preoperatively misdiagnosed as uterine leiomyoma or endometrial carcinoma because of the lack of features.…”

Section: First Author Age Presentation Misdiagnosis Diagnosis Symptom...mentioning

confidence: 99%

“…HG‐ESS is often preoperatively misdiagnosed as uterine leiomyoma or endometrial carcinoma because of the lack of features. Natural course and optimal treatments are currently unclear 5 . Surgery is the cornerstone of its treatment, and despite a lack of strong evidence for effective adjuvant therapy, chemotherapy and radiotherapy should be offered 5 .…”

Section: First Author Age Presentation Misdiagnosis Diagnosis Symptom...mentioning

confidence: 99%

See 1 more Smart Citation

First case of intracaval recurrence of high‐grade endometrial stromal sarcoma: A case report

Mandato

Valli

Silvotti

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…The preferred surgical treatment is en bloc total hysterectomy with or without bilateral salpingo-oophorectomy. Lymphadenectomy is not indicated in patients without macroscopically involved lymph nodes and should not be recommended unless the patient has evident extrauterine involvement or clinically suspicious enlarged nodes [ 6 , 7 , 8 , 9 ]. The Federation of Gynecology and Obstetrics (FIGO) staging should be used to stage US [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

New Insights into Hormonal Therapies in Uterine Sarcomas

Maccaroni

Lunerti

Agostinelli

et al. 2022

Cancers

View full text Add to dashboard Cite

Uterine sarcoma (US) is a rare mesenchymal malignant cancer type, accounting for 3–7% of uterine malignancies. US prognosis is still poor due to high local and distant recurrence rates. As for molecular features, US may present variable oestrogen receptor (ER) and progesterone receptor (PR) expressions, mostly depending on histotype and grading. Surgery represents the mainstay of treatment for early-stage disease, while the role of adjuvant chemotherapy or local radiotherapy is still debated and defined on the basis of histotype, tumour grading and stage. In metastatic setting, uterine sarcomas’ treatment includes palliative surgery, a metastases resection, chemotherapy, hormonal therapy and targeted therapy. As for the chemotherapy regimen used, drugs that are considered most effective are doxorubicin (combined with ifosfamide or alone), gemcitabine combined with docetaxel and, more recently, trabectedin or pazopanib. Hormonal therapies, including aromatase inhibitors (AIs), progestins and gonadotropin-releasing hormone analogues (GnRH-a) may also represent an effective option, in particular for low-grade endometrial stromal sarcoma (LGESS), due to their favourable toxicity profile and patients’ compliance, while their role is still under investigation in uterine leiomyosarcoma (uLMS), high-grade endometrial stromal sarcoma (HGESS), undifferentiated uterine sarcoma (USS) and other rarer US. The present review aims to analyse the existing evidence and future perspectives on hormonal therapies in US, in order to clarify their potential role in daily clinical practice.

show abstract

Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa’ italiana di Ginecologia E Ostetricia)

Cited by 29 publications

References 138 publications

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

First case of intracaval recurrence of high‐grade endometrial stromal sarcoma: A case report

New Insights into Hormonal Therapies in Uterine Sarcomas

Contact Info

Product

Resources

About